GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

divozilimab   Click here for help

GtoPdb Ligand ID: 13087

Synonyms: BCD 132 | BCD-132 | Ivlizi®
Approved drug Immunopharmacology Ligand
divozilimab is an approved drug (Russia (2023))
Compound class: Antibody
Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD20 (membrane-spanning 4-domains, subfamily A, member 1) Primary target of this compound Hs Antibody - - - -
⤷